ArticleNeuro-oncology practice2025
Clinical outcomes and management of
Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Utility of digital PCR for detecting TERT promoter mutations and CDKN2A homozygous deletion in meningioma.Brain tumor pathology · 2026Article
- Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review.Frontiers in oncology · 2026Article
- Hemizygous deletion ofNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of Methods: Demographic and clinical data were compiled for patients with IDH-mutant astrocytomas across multiple oncology centers and databases. Findings were supplemented with patterns of care survey circulated to Australian neuro-oncology centers and neuro-pathologists. Results: Patients were divided into the following cohorts: Conclusion: This exploratory study supports the importance of molecular profiling in glioma diagnoses and the prognostic utility of current classification systems. However future research into the optimal therapy for these patients is needed in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.